Back to results
US 8,026,055 B2Granted
Materials and methods for prognosing lung cancer survival
AssigneeUniversity Health Network
InventorsMing Sound Tsao, Suzanne Lau, Paul Boutros, Melania Pintilie, Sandy Der, Frances A. Shepherd, Igor Jurisica, Linda Penn
Life of this patent
Estimating the term…
Abstract
The invention provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups. The invention also includes kits for use in the methods of the invention.
Claims13
A method of prognosing a subject with early stage non-small cell lung cancer (NSCLC), comprising the steps of:
- (a) determining the expression levels of STX1A, HIF1A, CCT3, MAFK, RNF5 and HLA-DPB1 in a lung tumor test sample from the subject;
- and
- (b) comparing the expression levels so determined with expression levels of STX1A, HIF1A, CCT3, MAFK, RNF5 and HLA-DPB1 in a lung tumor control from an early stage NSCLC subject or group of early stage NSCLC subjects,
- wherein higher levels of STX1A, HIF1A, CCT3, MAFK, and RNF5 and lower levels of HLA-DPB1 in the subject as compared to the control indicates a poor prognosis;
- or
- (c) determining the expression levels of STX1A, CCR7, and HIF1A in a lung tumor test sample from the subject;
- and
- (d) comparing the expression levels so determined with expression levels of STX1A, CCR7, and HIF1A in a control from an early stage NSCLC subject or group of early stage NSCLC subjects,
- wherein higher levels of STX1A and HIF1A and lower levels of CCR7 in the subject as compared to the control indicates a poor prognosis.
6 more elements
Dependencies are inferred from the claim text.